UNEWi022-B
F181 18.2
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | UNEWi022-B |
| Alternative name(s) |
F181 18.2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
Provider |
|
| Depositor | University of Newcastle (UNEW) |
| Owner | Institute of Genetic Medicine |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
| Derivation country | United Kingdom |
External Databases |
|
| hPSCreg | UNEWi022-B |
| BioSamples | SAMEA4092901 |
| Cellosaurus | CVCL_IT86 |
| ECACC | 66540178 |
| CLO | CLO_0101590 |
| Wikidata | Q54991165 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information#
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 85-89 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA4092876 |
hIPSC Derivation#
General |
|
| Source cell type |
fibroblast of dermis |
| Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
|
| Age of donor (at collection) | 85-89 |
| Passage number reprogrammed | P4 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Based on morphology, growth rate and expression of SSEA4 and NANOG |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR |
| Passage method | EDTA |
| Surface coating | Matrigel / Geltrex |
| O2 concentration | 20 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA1 |
No |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No clinically significant imbalance was detected
Passage number: P13
Karyotyping method:
Molecular karyotyping by SNP array
|
Other Genotyping (Cell Line) |
|